Digitisation | November 11, 2025
Nitinotes secures CE mark for automated suturing platform ‘EndoZip’
Enabling a new era in minimally invasive obesity treatment across Europe
Enabling a new era in minimally invasive obesity treatment across Europe
Relmada expects to initiate its Phase 3 program in the first half of 2026
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Subscribe To Our Newsletter & Stay Updated
